CD274 and lymphoma: Based on initial studies that suggested potential antitumor activity in hematologic malignancies with anti‐PD‐1/PD‐L1 therapeutics, we hypothesized that the T‐cell‐mediated anti‐tumor responses seen after treatment with durvalumab might act synergistically with standard‐of‐care treatments for lymphoma and CLL, ultimately resulting in enhanced efficacy without compromising safety.17, 18